Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sildenafil for the Prevention of Right Heart Failure Following Continuous-Flow Left Ventricular Assist Device Implantation (The REVAD Study)

NCT03356353 is registered in ClinicalTrials.gov with University of Calgary as lead sponsor.

NCT NCT03356353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03356353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sildenafil for the Prevention of Right Heart Failure Following Continuous-Flow Left Ventricular Assist Device Implantation (The REVAD Study)
Lead sponsor
University of Calgary
Phase
Phase 3
Overall status
Unknown status
Start date
March 12, 2018
Completion date
January 31, 2022
Enrollment
24 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

end stage heart failure